MIRA director granted 50,000 stock options

MIRA PHARMACEUTICALS, INC. director Edward Clouston MacPherson received a grant of 50,000 stock options for common stock.

Accepted by SEC EDGAR 06/15/2026 - 05:00 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

MIRA PHARMACEUTICALS, INC. director Edward Clouston MacPherson received a grant of 50,000 stock options for common stock. The options have an exercise price of $0.94 per share and expire on June 12, 2036.

According to the grant terms, 50% of the options vest on the six-month anniversary of the June 12, 2026 grant date, and the remaining 50% vest on the one-year anniversary. Following this award, he holds 50,000 stock options directly.

Insider Trade Summary

Grant/Award: 50,000 shares

Grant/Award 1 txn

Insider MacPherson Edward Clouston

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (right to buy)	50,000	$0.00	$0.00

Holdings After Transaction: Stock Options (right to buy) — 50,000 contracts (Direct)

Holdings Before and After: Stock Options (right to buy), 0 to 50,000 contracts (Direct)

Footnotes (3)

1. F1. The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on June 12, 2026.
2. F2. The stock options were issued to the Reporting Person on June 12, 2026 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date.
3. F3. Represents 50,000 stock options that were issued to the Reporting Person on June 12, 2026, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $0.94 each.

Key Figures

Options granted: 50,000 options Exercise price: $0.94 per share Expiration date: June 12, 2036 +3 more

6 metrics

Options granted 50,000 options Stock options for common stock granted on June 12, 2026

Exercise price $0.94 per share Exercise price of granted stock options

Expiration date June 12, 2036 Option expiration for the 50,000 granted options

Post-grant option holdings 50,000 options Total stock options held following the reported grant

Initial vesting 50% at six months Half of options vest six months after June 12, 2026

Final vesting 50% at one year Remaining half vests one year after June 12, 2026

Key Terms

Stock Options, exercise price, 2022 Omnibus Incentive Plan, vesting

4 terms

Stock Options financial

"Represents 50,000 stock options that were issued to the Reporting Person"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

exercise price financial

"at an exercise price of $0.94 each"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

2022 Omnibus Incentive Plan financial

"pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated"

vesting financial

"50% of the options vest on the six-month anniversary of the grant date"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did MIRA (MIRA) director Edward MacPherson report in this Form 4?

Edward Clouston MacPherson reported receiving 50,000 stock options for MIRA PHARMACEUTICALS common stock. The options were granted as a compensation award and give him the right to buy shares at a fixed exercise price if they vest and he chooses to exercise.

How many MIRA PHARMACEUTICALS (MIRA) options were granted to the director?

The director was granted 50,000 stock options linked to MIRA PHARMACEUTICALS common stock. These options represent the right to purchase up to 50,000 shares if exercised, subject to the stated vesting schedule and the exercise price set in the award.

What is the exercise price of the MIRA (MIRA) stock options granted?

The stock options have an exercise price of $0.94 per share. This means the director can buy MIRA PHARMACEUTICALS common stock at $0.94, once the options vest and before they expire, regardless of the market price at that future time.

When do the granted MIRA PHARMACEUTICALS options vest for the director?

The options vest in two equal halves after the grant date. Fifty percent vest on the six-month anniversary of June 12, 2026, and the remaining fifty percent vest on the one-year anniversary, creating a staged vesting schedule over the first year.

When do Edward MacPherson’s MIRA (MIRA) stock options expire?

The granted stock options expire on June 12, 2036. After that expiration date, any unexercised options will lapse and can no longer be used to buy MIRA PHARMACEUTICALS common stock, even if they previously vested under the grant terms.

Under what plan were the MIRA PHARMACEUTICALS (MIRA) options granted?

The options were granted under MIRA PHARMACEUTICALS’ 2022 Omnibus Incentive Plan, as amended and restated. This plan governs equity-based compensation awards, including stock options, and sets the framework for vesting, exercise price, and other key grant conditions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MacPherson Edward Clouston

(Last) (First) (Middle)

C/O MIRA PHARMACEUTICALS, INC.

1200 BRICKELL AVE. SUITE 1950 #1183

(Street)

MIAMI FLORIDA 33131

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MIRA PHARMACEUTICALS, INC. [ MIRA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/12/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (right to buy)	$0.94(1)	06/12/2026		A		50,000		(2)	06/12/2036	Common Stock	50,000	$0	50,000(3)	D

Explanation of Responses:

1. The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on June 12, 2026.

2. The stock options were issued to the Reporting Person on June 12, 2026 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date.

3. Represents 50,000 stock options that were issued to the Reporting Person on June 12, 2026, that vest in equal halves on the six and 12 month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $0.94 each.

	/s/ Edward MacPherson	06/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)